Clamidoxic Acid

Clamidoxic Acid

SCHEMBL525147

O=C(O)COc1ccccc1NC(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
MAPT P10636 3/20 0.54
HPGD P15428 1/20 0.54
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
ALDH1A1 P00352 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
SLC16A3 O15427 1/20 0.52
SSTR3 P32745 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
NOD2 Q9HC29 1/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
HTT P42858 1/20 0.50
KCNH2 Q12809 1/20 0.50
PLAU P00749 1/20 0.49
LMNA P02545 1/20 0.49
AHR P35869 1/20 0.49
PDE4D Q08499 1/20 0.48
HDAC1 Q13547 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12427892 0.83 MAPK1 (0.58) HPGDNPC1RAB9AALDH1A1KMT2A
SCHEMBL12190105 0.82 SMN1; SMN2 (0.60) MAPTALDH1A1NPSR1LMNAHDAC1
SCHEMBL27716603 0.79 PYGM (0.58) MAPTNPC1RAB9AALDH1A1NPSR1
SCHEMBL20228918 0.78 MAPT (0.76) KDM4EMAPTHPGDNPC1RAB9A
SCHEMBL29870304 0.78 MAPT (0.76) KDM4EMAPTHPGDNPC1RAB9A
SCHEMBL7119403 0.75 PYGM (0.76) NPC1RAB9AALDH1A1SLC16A3KMT2A
SCHEMBL8914972 0.74 LMNA (0.69) KDM4EMAPTHPGDNPC1RAB9A
SCHEMBL493680 0.73 ALDH1A1 (0.49) ALDH1A1KCNH2
SCHEMBL7360102 0.73 BRD4 (0.69) KDM4EMAPTHPGDNPC1RAB9A
SCHEMBL3645013 0.73 MEN1 (0.74) KDM4EMAPTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
US-9283283-B2 Hyaluronic acid based hydrogel and use thereof in surgery MERO S.R.L. (IT) 2016-03-15 US disclosed
EP-2598180-B1 HYALURONIC ACID BASED HYDROGEL AND USE THEREOF IN SURGERY NOVAGENIT S R L (IT) 2015-12-09 EP disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
WO-1995004533-A2 TREATMENT OF RHEUMATOID ARTHRITIS WITH THALIDOMIDE ALONE OR IN COMBINATION WITH OTHER ANTI-INFLAMMATORY AGENTS ANDRULIS PHARMACEUTICALS CORPORATION (US) 1995-02-16 WO disclosed
EP-0355095-B1 PHARMACOLOGICAL AGENT-LIPID SOLUTION PREPARATION THE LIPOSOME COMPANY, INC. (US) 1993-08-04 EP disclosed
US-5154930-A Pharmacological agent-lipid solution preparation THE LIPOSOME COMPANY, INC. (US) 1992-10-13 US disclosed
EP-0249561-B1 COMPOSITIONS USING LIPOSOME-ENCAPSULATED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS THE LIPOSOME COMPANY, INC. (US) 1992-05-13 EP disclosed
EP-0289262-A2 Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1988-11-02 EP disclosed
WO-1987007506-A1 METHODS AND COMPOSITIONS USING LIPOSOME-ENCAPSULATED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS THE LIPOSOME COMPANY, INC. (US) 1987-12-17 WO disclosed
EP-0249561-A2 Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs THE LIPOSOME COMPANY, INC. (US) 1987-12-16 EP disclosed